FDA grants #OrphanDrug designation to Kamada’s diabetes drug

In Uncategorized by Caroline Hornby

kamada diabetes drug given fda orphan drug designation Kamada has been granted an Orphan Drug Designation by the FDA for its Alpha-1 Antitrypsin (AAT) product to treat type 1 diabetes. The company is currently undergoing a Phase I/II clinical trial with AAT by IV route of administration.

Kamada plans to publish an interim and/or the final reports during 2012.

David Tsur, Chief Executive Officer of Kamada said: "We are excited to enter the diabetes field and hope to bring a global breakthrough in the treatment of juvenile diabetes and potential cure."

Read the full story here.

To learn more about orphan drugs, check out the World Orphan Drug Congress USA.